Related Experiment Videos
Prognostic factors for biologic therapy in kidney cancer
1Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Box 510, New York, NY 10021, USA. druckerb@mskcc.org
Abstract:
Renal cell cancer is resistant to most forms of therapy. Cytokine therapy with either interleukin-2 or interferon-alpha yields the best results, with response rates from 10% to 20%. Therapy is not without toxicity, which means that the majority of patients treated with cytokines suffer toxicity without any therapeutic benefit. Recent endeavors have tried to find new ways to identify responders to cytokine therapy. Prognostic factors, such as good performance status, lack of anemia, normal calcium, normal lactate dehydrogenase, and prior nephrectomy, correlate with an increased likelihood of responding to cytokine therapy. Recent studies have examined whether altered subpopulations of lymphocytes, the presence of eosinophils, or altered levels of cytokines can predict response to cytokine therapy. Although prior nephrectomy does correlate with improved survival while the patient is receiving cytokine therapy, it is unclear if this is due to a significant alteration in the tumor's response to cytokine or some unrelated benefit from surgery. Further studies are needed to confirm the current immune parameters and disease characteristics that suggest a better response to cytokine therapy.
Insights
Identifying patients likely to respond to cytokine therapy for renal cell cancer is crucial. Factors like good performance status and normal bloodwork can predict better outcomes, reducing unnecessary toxicity.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Renal cell cancer (RCC) exhibits resistance to conventional therapies.
- Cytokine therapy, including interleukin-2 and interferon-alpha, offers limited response rates (10-20%) for RCC.
- Significant toxicity associated with cytokine therapy necessitates identification of predictive biomarkers.
Purpose of the Study:
- To explore prognostic factors and immune parameters that predict response to cytokine therapy in renal cell cancer patients.
- To differentiate between tumor response and unrelated benefits from prior nephrectomy in predicting survival during cytokine therapy.
Main Methods:
- Review of existing studies on prognostic factors for cytokine therapy response in RCC.
- Analysis of immune parameters such as lymphocyte subpopulations, eosinophils, and cytokine levels.
- Correlation of clinical factors (performance status, anemia, calcium, LDH, prior nephrectomy) with treatment outcomes.
Main Results:
- Good performance status, absence of anemia, normal calcium, normal lactate dehydrogenase, and prior nephrectomy are associated with a higher likelihood of response to cytokine therapy.
- Prior nephrectomy correlates with improved survival during cytokine therapy, though the mechanism is unclear.
- Altered lymphocyte subpopulations, eosinophil presence, and cytokine levels are under investigation as potential predictors.
Conclusions:
- Several clinical and disease characteristics can help identify patients more likely to benefit from cytokine therapy for renal cell cancer.
- Further research is required to validate these immune parameters and disease characteristics for accurate response prediction.
- Optimizing patient selection for cytokine therapy can minimize toxicity and improve therapeutic benefit in renal cell cancer treatment.